<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00878176</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 09-2-005</org_study_id>
    <nct_id>NCT00878176</nct_id>
  </id_info>
  <brief_title>Sacral Neuromodulation Test With Bilateral First Stage Tined Lead Procedure in Patients With Non-obstructive Urinary Retention: A Pilot Study</brief_title>
  <official_title>Sacral Neuromodulation Test With Bilateral First Stage Tined Lead Procedure in Patients With Non-obstructive Urinary Retention: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether bilateral sacral nerve stimulation with&#xD;
      First stage tined lead placement test is more effective than unilateral stimulation, among&#xD;
      patients with non obstructive urinary retention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the eligibility for SNM therapy. This is defined as yes or no. A patient is eligible for the therapy when he or she can void again or the volume increased with at least 50%, and the catheterized volume is less then 100ml.</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete or incomplete urinary retention</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Urinary Retention</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Crossover study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>First stage tined lead procedure</intervention_name>
    <description>bilateral first stage tined lead placement</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who signed the informed consent&#xD;
&#xD;
          -  Patients (male and female), aged between 18-70 years, with non obstructive urinary&#xD;
             retention.&#xD;
&#xD;
        Two specific subcategories of retention are included&#xD;
&#xD;
          1. Incomplete voiding or incomplete retention (&gt;100 cc residual) such as hesitancy or&#xD;
             intermittency, that are due to an acontractile detrusor or due to urethral sphincter&#xD;
             overactivity. The overactivity of the sphincter may occur in absence of detrusor&#xD;
             contraction and may be the cause of the lack of detrusor activity.&#xD;
&#xD;
          2. Complete retention. These individuals are completely unable to void.&#xD;
&#xD;
        All patients must have the potential for storing an adequate volume of urine:&#xD;
&#xD;
        i.e., at least 100 ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known psychiatric disorders&#xD;
&#xD;
          -  Current or plans of pregnancy&#xD;
&#xD;
          -  Known neurologic diseases or impairment; including DM (severe or uncontrolled&#xD;
             diabetes; or diabetes with peripheral nerve involvement), spinal cord injury, MS&#xD;
&#xD;
          -  Reiter's syndrome&#xD;
&#xD;
          -  Concomitant medical conditions that would limit the success of the procedure such as:&#xD;
             active degenerative disc disease, spinal cord injury&lt; 6 months old, bleeding&#xD;
             complications, CVA&lt; 6 months old etc.&#xD;
&#xD;
          -  Extra urethral incontinence&#xD;
&#xD;
          -  Pelvic pain of uncertain etiology that is not associated with a voiding dysfunction or&#xD;
             where pelvic pain is the primary complaint/ diagnosis.&#xD;
&#xD;
          -  Anatomic obstructive voiding disorders&#xD;
&#xD;
          -  Current urinary tract infection&#xD;
&#xD;
          -  Malignancy of urinary tract&#xD;
&#xD;
          -  Severe grade III/ IV pelvic prolapse, cystocele, urethrocele, enterocele&#xD;
&#xD;
          -  Proven interstitial cystitis or clinical symptoms of interstitial cystitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip van Kerrebroeck, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>dept Urology, Maastricht University Hospital</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>April 7, 2009</study_first_submitted>
  <study_first_submitted_qc>April 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2009</study_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sacral neuromodulation therapy</keyword>
  <keyword>urinary retention</keyword>
  <keyword>screening</keyword>
  <keyword>non obstructive urinary retention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

